QHSLab, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>QHSLab, Inc. filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing its financial status and corporate history.</b>

AI Summary

QHSLab, Inc. (USAQ) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. QHSLab, Inc. filed a 10-Q report for the period ending March 31, 2024. The company was formerly known as USA EQUITIES CORP. and AMERICAN BIOGENETIC SCIENCES INC. QHSLab, Inc. is incorporated in Nevada (NV). The company's SIC code is 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS). The filing was made on May 13, 2024.

Why It Matters

For investors and stakeholders tracking QHSLab, Inc., this filing contains several important signals. This filing provides investors and analysts with the latest financial performance and operational details of QHSLab, Inc. for the first quarter of 2024. Understanding the company's historical name changes and its industry classification is crucial for assessing its long-term strategy and market position.

Risk Assessment

Risk Level: low — QHSLab, Inc. shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial disclosures without immediate indicators of significant risk or opportunity.

Analyst Insight

Monitor future filings for detailed financial statements and management discussion to assess QHSLab, Inc.'s performance and strategic direction.

Key Numbers

• 2024-03-31 — Reporting Period End Date (Conformed period of report)
• 2024-05-13 — Filing Date (Filed as of date)
• 1231 — Fiscal Year End (Fiscal year end)
• 3841 — SIC Code (Standard Industrial Classification)

Key Players & Entities

• QHSLab, Inc. (company) — Filer name
• USA EQUITIES CORP. (company) — Former company name
• AMERICAN BIOGENETIC SCIENCES INC (company) — Former company name
• NV (location) — State of incorporation
• 3841 (industry_code) — Standard Industrial Classification
• WEST PALM BEACH (location) — Business address city
• FL (location) — Business address state
• 2024-05-13 (date) — Filing date

FAQ

Industry Context

QHSLab, Inc. operates within the Surgical & Medical Instruments & Apparatus industry (SIC 3841). This sector involves the manufacturing and distribution of medical devices and equipment.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to submit regular financial disclosures to the SEC.

What Investors Should Do

1. Review the full 10-Q filing for detailed financial statements (balance sheet, income statement, cash flow).
2. Analyze any management discussion and analysis (MD&A) section for insights into operational performance and future outlook.
3. Research the company's history, including former names and incorporation details, to understand its evolution.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-13: Filing Date — Date the 10-Q report was officially submitted to the SEC.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides a comprehensive overview of a company's financial performance during a specific quarter.)

SIC Code

Standard Industrial Classification code used to classify industries. (Helps categorize QHSLab, Inc. within the broader economic landscape, specifically in medical instruments.)

Year-Over-Year Comparison

This is the initial 10-Q filing for QHSLab, Inc. for the period ending March 31, 2024, following its corporate name changes.

Key Financial Figures

• $0.0001 — nge on Which Registered Common Stock, $0.0001 Par Value USAQ NA Indicate by che

Filing Documents

• form10-q.htm (10-Q) — 538KB
• ex31.htm (EX-31) — 11KB
• ex32.htm (EX-32) — 7KB
• 0001493152-24-018786.txt (&nbsp;) — 3386KB
• usaq-20240331.xsd (EX-101.SCH) — 27KB
• usaq-20240331_cal.xml (EX-101.CAL) — 40KB
• usaq-20240331_def.xml (EX-101.DEF) — 122KB
• usaq-20240331_lab.xml (EX-101.LAB) — 231KB
• usaq-20240331_pre.xml (EX-101.PRE) — 188KB
• form10-q_htm.xml (XML) — 424KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS. 4 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 19 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES. 23

- OTHER INFORMATION

PART II - OTHER INFORMATION ITEM 6. EXHIBITS. 24 2 Cautionary Note Regarding Forward-Looking Statements This report contains forward-looking statements. Certain of the matters discussed herein concerning, among other items, our operations, cash flows, financial position and economic performance including, in particular, future sales, product demand, competition and the effect of economic conditions, include forward-looking statements. Forward-looking "anticipates," "intends," "plans," "believes," "estimates" and similar expressions. Although we believe that the forward-looking statements contained in this report are based upon reasonable assumptions, these statements and other projections contained herein expressing opinions about future outcomes and non-historical information, are subject to uncertainties and, therefore, there is no assurance that the outcomes expressed in these statements will be achieved. Investors are cautioned that forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the expectations expressed in forward-looking statements contained herein. Given these uncertainties, you should not place any reliance on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You are advised, however, to consult any additional disclosures we make in our reports filed with the Securities and Exchange Commission ("SEC"). 3 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS (unaudited) Condensed Consolidated Balance Sheets – March 31, 2024 (unaudited) and December 31, 2023 5 Condensed Consolidated

View Full Filing

View this 10-Q filing on SEC EDGAR